Free Republic 3rd Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $25,328
31%  
Woo hoo!! And we're now over 31%!! Thank you all very much!! God bless.

Posts by terrygd

Brevity: Headers | « Text »
  • Convicted border agent tells his story

    08/09/2006 3:58:52 PM PDT · 117 of 132
    terrygd to snowtigger

    Someone just posted this on another board. Talk about lack of border security. Now they're financing them.

    Shipping-corridor deal cuts heart out of heartland by Phyllis Schlafly
    Townhall.com - August 7, 2006


    Grass-roots Americans of all parties and economic classes rose up out of their political apathy a few months ago and forced President George W. Bush to reverse his administration's decision to allow a Middle East government to own America's major ports. But the push for foreign ownership continues: the next port scheduled to be taken over is Kansas City, Mo.


    Even though public schools stopped teaching geography a couple of decades ago, most Americans (especially residents of the Show Me State) are surprised to learn that Kansas City (where the only waves are "amber waves of grain") is a port. We are also surprised, and shocked, to discover that Mexico will be running its own inspection facility there. The plan, shrouded in secrecy, has been in the works for at least three years, but it is now coming to light because of the diligent use of Missouri's Sunshine law by concerned citizens. Joyce Mucci and Francis Semler forced the release of the e-mails from Kansas City to Mexico, including one admitting that "The space (in Kansas City) would need to be designated as Mexican sovereign territory."


    SmartPort representatives are now running away from this written admission, blaming "the problems and pressure the media attention has created." However, the stubborn sovereignty issue won't go away; the plan does involve setting up Mexican customs officials in downtown Kansas City.


    The mechanism for this deal is a "nonprofit" business economic development corporation called Kansas City SmartPort Inc., whose president is Chris J.F. Gutierrez. The deal calls for Kansas City to lease the valuable property at 1447 Liberty St.


    As laid out on SmartPort's Web site, the plan is to enable products made in China to travel in sealed "containers nonstop from the Far East by way of Mexico," through "a ships-to-rail terminal at the port of Lazaro Cardenas, Mexico," then up "the evolving trade corridor" to Kansas City, Mo., where they would have their first inspection. A Kansas City SmartPort brochure explains further: "Kansas City offers the opportunity for sealed cargo containers to travel to Mexican port cities with virtually no border delays."


    A key purpose of the project is to take jobs away from U.S. longshoremen in Los Angeles and Long Beach, Calif and replace them with Mexican laborers. U.S. truck drivers and railroad workers will likewise be replaced by Mexicans.


    The port of Lazaro Cardenas, on the west coast of southern Mexico, is controlled by Hutchison Whampoa, the same giant Hong Kong shipping firm that owns the ports at both ends of the Panama Canal. Chinese-made goods will be carried by Kansas City Southern Railway de Mexico directly to Kansas City, where freight will be distributed east and west and on to Canada.


    Kansas City Southern was originally a belt railway around Kansas City but, after buying various Mexican rail companies and tracks, KCS controls a 2,600-mile artery from Lazaro Cardenas to Kansas City. KCS President Michael Haverty was one of five U.S. businessmen who met with President Bush, Mexican President Vicente Fox and Canadian Prime Minister Stephen Harper at their March summit in Cancun, Mexico.


    Mexico was at first expected to pay for the big, expensive machines to conduct high-tech gamma-ray screening for drive-through inspections of containers, but Mexico declined the honor. SmartPort has applied for a $1.5 million grant from the U.S. Economic Development Administration (i.e., to get the U.S. taxpayers to pay for the machines). The Kansas City City Council has already earmarked $2.5 million in loans and $600,000 in direct aid to SmartPort, which would build and own the facility and then sublet it to the Mexican government. The cost could go as high as $6 million because Kansas City has an existing lease that runs through 2045 on the same property with the 107-year-old American Royal, which uses that land for its annual livestock/rodeo/barbecue event.


    The last piece in finalizing this project is getting the U.S. State Department to approve the Mexican operation on U.S. soil by signing off on what is called the C-175 document. It has already been approved by U.S. Customs. Meanwhile, NASCO (North America's SuperCorridor Coalition Inc.), another nonprofit business organization, has taken on the mission of building an "international, integrated and secure, multimodal transportation system" from Lazaro Cardenas through Kansas City and up to Winnipeg, Canada. This will allow Mexican trucks to haul goods along a 12-lane superhighway through the heartland of the United States.

  • Marburg Surveillance Project Thread II

    09/15/2005 11:36:56 AM PDT · 761 of 766
    terrygd to Oorang

    Several promising aspects about TARVACIN’s potential as an ANTI-VIRAL (and even Anti-Cancer) treatment (ALL THESE THINGS REMAIN TO BE PROVEN IN HUMAN TRIALS):

    IT APPEARS TO BE UNIVERSAL:
    Bernard Wolfson in his 7-16-05 O.C.R. “High Hopes” article said, “What if someone told you they had a drug that could fight Cancer and nearly every human Virus from HIV to Hepatitis C, and from Ebola to the common flu? You might be a little surprised, a little curious, a little excited - and more than a little incredulous… The reason Tarvacin appears to have such a broad range of uses is that it targets not any specific cancer or virus, but rather a substance found in the membranes of all cells. When cells become malignant, or are infected by a virus, the substance - known as a phospholipid - moves from the inside of the membrane to the outer surface, allowing Tarvacin to bind with it. The binding marks the cell, raising a red flag that alerts the immune system to the presence of a foreign body. With viral infections, the body's white blood cells attack the viruses. With cancer, the immune system appears to destroy the blood vessels of a tumor, depriving it of the nutrients it needs to grow. ‘The concept is almost so simple it's hard to believe no one picked up on it before,’ says Steven King, Peregrine’s CEO Peregrine.” [http://tinyurl.com/9e6gf ]
    ###This from Thorpe’s patent app #20040161429 (filed 8-15-03, pub. USPO 8-19-04), titled ‘Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipid’: [0909] “the spectrum of viral treatment for the present invention extends to any virus, whether enveloped or not, DNA or RNA. …the invention is not limited to the treatment of enveloped viruses alone, nor to any particular virus, which is an important advantage. [1302] “the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent.” [ http://tinyurl.com/6pdny ]
    ###CEO King 6-15-05, “....Examples of enveloped viruses include Marburg virus, Lassa fever, Ebola, HIV, Hepatitis C, Influenza [incl. Avian]. Secondly, as I'll show you later in some preclinical data, Tarvacin has shown the ability to arrest the development of disease even in late stages of infection. And thirdly, Tarvacin is expected to recognize not just the known enveloped viruses that are here today, but new enveloped viruses that will undoubtedly become available and will have mutated and become new viral strains over the next years to come."
    [ http://tinyurl.com/coomw & http://tinyurl.com/e2hxh ]
    ###Michael Brush’s 7-28-05 “Envelope Please” article, “Most of the excitement right now surrounds potential treatments of the so-called “envelope” viruses – the ones that envelope themselves with bits the host cell membrane as they exit the host cell. The “envelope” viruses read like a top 10 list of diseases you’re most likely to get, and really don’t want. They range from Influenza and Hepatitis B and C, to Herpes, West Nile, Dengue, HIV, SARS, Avian flu and many of the potential bio-terror “hemorrhagic” viruses, like Ebola. [http://tinyurl.com/9z7yf ]

    IT APPEARS TO BE SAFE:
    From Thorpe video 10-24-04: “Understanding Tarvacin”, incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities: “That's an extraordinary result, I don't know of any other antiviral agent that is known to protect against Lassa Fever. And we've also shown similar results in cytomegalovirus... at that dose we've never seen any sign of toxicity in mice or monkeys; about 14 species treated with the therapeutic dose. And that's thousands of mice & monkeys. And even if you increase the dose to 10 mg/kg, that's 10x the therapeutic dose. So the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there.”
    [http://tinyurl.com/8b6kr & http://tinyurl.com/dou8t ]
    ###From Thorpe’s APT (AntiPS/3G4/Tarvacin) patent app #20040161429 (pub. USPO 8-19-04):
    [1298] “The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed.” [http://tinyurl.com/6pdny ]
    ###From Thorpe’s Aug03-Jan08 $1.68mm NIH/NIAID grant for research using 3G4 as ‘Novel Anti-Viral Agents for Treating Lassa Fever’, “the phospholipids that they recognize have the same structure and cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans. The antibodies arenot toxic to mice, even when administered in high doses for prolonged periods of time.” [http://tinyurl.com/5ntcm ]

    IT APPEARS VIRUSES CAN’T BECOME RESISTANT TO IT:
    Again, from the Brush article, “A great thing about Peregrine’s approach is that viruses can’t mutate to fight off the Tarvacin attack. That’s because Tarvacin keys in on anomalies in the cell membrane – the confused phospholipids -- that viruses don’t know how to fix. ‘Since it is not made by the virus, it is not mutable by the virus,’ says Peregrine CEO Steven King. ‘It is not something the virus can change, to get away from therapy.’” [http://tinyurl.com/9z7yf ]
    ###From the Wolfson article, “Scientists say Tarvacin could have an advantage over other anti-viral drugs because viruses probably won't be able to evade it by mutating. ‘Mutation won't affect it because it's targeting a substance which is not intrinsic to the virus itself but to the host cell - so that substance will be there no matter what new form the virus takes,’ says Dr. Stephen M. Smith, a paid Peregrine consultant and chief of infectious diseases at the Seton Hall School of Graduate Medical Education in Orange, NJ.” [http://tinyurl.com/9e6gf ]
    ###CEO King 6-15-05, “Tarvacin recognizes a stable target common to all enveloped viruses that cannot easily be mutated because it is derived from the host, it's not encoded by the genome, but rather it's a stable structure of the virus particle.”
    [ http://tinyurl.com/coomw & http://tinyurl.com/e2hxh ]

    IT MAY EVEN CONFER VIRAL IMMUNITY:
    From Tarvacin.com, “Tarvacin provided significant protection in animals administered lethal viral loads of pichinde virus (a model of Lassa fever) with 50% of the Tarvacin treated animals surviving and none of the animals receiving control treatment surviving. Moreover, Tarvacin treated guinea pigs who survived the infection became immune to subsequent infections with the same viral strain. An interesting hypothesis still to be tested is whether treatment of one virus with APT agents confers protection against infection by other enveloped viruses. [http://tinyurl.com/cvfcm ]
    ###From BIO2005, “Animals lethally infected with Pichinde virus that survived following Tarvacin therapy had long term immunity to reinfection.” [http://tinyurl.com/dqf9t]

    = = = = = = =
    Remember, Tarvacin initiated a Ph1 Trial against HEP-C 8-8-2005:

    8-8-05: HEP-C Trial Inititates at Bach and Godofsky Infectious Diseases, Bradenton FL:
    "This phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic Hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy... The study is being conducted at Bach and Godofsky Infectious Diseases, the largest private infectious disease practice specializing in the treatment of viral hepatitis in the USA."
    http://ir.peregrineinc.com/phoenix.zhtml?c=74236&p=irol-newsArticle&ID=740477
    Bach & Godofsky Infectious Diseases in Bradenton, FL
    Principle Investigator: Dr. Eliot W. Godofsky
    Announcement 8-8-05: http://tinyurl.com/cltum
    Tarvacin Trials website: http://www.tarvacin.com
    Gov't info: http://clinicaltrials.gov/ct/show/NCT00128271
    ***Tarvacin HEP-C Trial Contacts:
    Peregrine: 800-694-5334, clinicalaffairs@peregrineinc.com
    Contact Bach & Godofsky directly: 941-746-2711 x39

    To learn more about Thorpe & Tarvacin:
    http://tinyurl.com/b9hdq - my amateur compilation of Articles, Quotes, Patents, History, etc.